ELTX Elicio Therapeutics, Inc.

Nasdaq elicio.com


$ 9.35 $ -0.70 (-6.97 %)    

Friday, 17-Oct-2025 15:59:51 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 9.35
$ 9.94
$ 9.10 x 1
$ 10.70 x 17
$ 9.18 - $ 9.94
$ 4.05 - $ 12.62
117,582
na
152.76M
$ 1.52
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-31-2025 12-31-2024 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-15-2024 03-31-2024 10-Q
7 03-29-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-12-2023 06-30-2023 10-Q
10 05-10-2023 03-31-2023 10-Q
11 03-17-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-15-2022 06-30-2022 10-Q
14 05-16-2022 03-31-2022 10-Q
15 03-30-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 05-17-2021 03-31-2021 10-Q
19 03-30-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 elicio-therapeutics-announces-planned-initiation-of-investigator-initiated-phase-1-trial-of-eli-002-7p-in-combination-with-chemotherapy-and-anti-pd1-checkpoint-inhibitor-in-borderline-and-resectable-pdac

Study will evaluate ELI-002 7P in combination with chemotherapy and a checkpoint inhibitor ("CPI") in the neoadjuvant s...

 elicios-eli-002-triggers-mkras-specific-t-cell-responses-in-99-of-phase-2-amplify-7p-trial-patients

ELI-002 induced mKRAS-specific T cell responses in 99% of evaluable patients (89 of 90) who were treated with the investigation...

 elicios-eli-002-vaccine-nearly-doubles-survival-slashes-death-and-relapse-risk-in-mkras-cancer-phase-1-data-published-in-nature-medicine

At extended median follow-up of 19.7 months, median overall survival ("OS") increased from 16.33 to 28.94 monthsClinica...

 elicio-therapeutics-publishes-follow-up-data-from-phase-1-amplify-201-study-in-nature-medicine

At extended median follow-up of 19.7 months, median overall survival ("OS") increased from 16.33 to 28.94 monthsClinica...

 elicio-therapeutics-q2-eps-066-misses-065-estimate

Elicio Therapeutics (NASDAQ:ELTX) reported quarterly losses of $(0.66) per share which missed the analyst consensus estimate of...

 elicios-pancreatic-cancer-vaccine-trial-clears-key-review-moves-ahead-without-changes

Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company"))), a clinical-stage biotechnology company de...

 hc-wainwright--co-maintains-buy-on-elicio-therapeutics-raises-price-target-to-13

HC Wainwright & Co. analyst Robert Burns maintains Elicio Therapeutics (NASDAQ:ELTX) with a Buy and raises the price tar...

 elicio-therapeutics-to-host-june-25-virtual-kol-event-at-200-pm-et-highlighting-urgent-need-and-phase-2-progress-of-amp-powered-eli-002-vaccine-for-mkras-driven-pancreatic-cancer

Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company"))), a clinical-stage biotechnology company de...

 elicio-therapeutics-q1-eps-087-misses-083-estimate

Elicio Therapeutics (NASDAQ:ELTX) reported quarterly losses of $(0.87) per share which missed the analyst consensus estimate of...

 hc-wainwright--co-reiterates-buy-on-elicio-therapeutics-maintains-10-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Elicio Therapeutics (NASDAQ:ELTX) with a Buy and maintains $10 price...

 elicio-therapeutics-fy-2024-gaap-eps-425-misses-356-estimate-as-of-december-31-2024-cash-and-cash-equivalents-were-176m-including-10m-in-gross-proceeds-from-january-2025-registered-direct-offering-the-company-expects-cash-runway-into-q4-2025

Elicio Therapeutics (NASDAQ:ELTX) reported quarterly losses of $(4.25) per share which missed the analyst consensus estimate of...

 elicio-therapeutics-gets-fda-support-to-advance-cancer-immunotherapy-plans-phase-3-trial-for-eli-002

Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio Therapeutics" or "Elicio"))), a clinical-stage biotechnology co...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION